Dr. Lieu Discusses the Focus of Future Research in mCRC
September 12th 2019Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses where future research should focus in metastatic colorectal cancer.
Dr. Davis on Immunotherapy in HER2-Positive Gastric/GEJ Cancer
September 4th 2019S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses an investigational immunotherapy combination being explored in patients with HER2-positive gastric and gastroesophageal junction (GEJ) cancer.
Dr. Davis on the Role of Ramucirumab in Gastric/GEJ Cancer
August 20th 2019S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses the role of ramucirumab (Cyramza) in the treatment of patients with gastric/gastroesophageal junction (GEJ) adenocarcinoma.
Dr. Lieu Discusses the Rationale for Combined MEK/VEGF/PD-1 Inhibition in CRC
August 8th 2019Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses the rationale for combined MEK, VEGF, and PD-1 inhibition in microsatellite stable (MSS) colorectal cancer (CRC).
Dr. Lieu on the Predictive Value of BRAF V600E Mutations in mCRC
July 26th 2019Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associate director for clinical research, at the University of Colorado Cancer Center, discusses the predictive value of BRAF V600E mutations in metastatic colorectal cancer (mCRC).
Dr. Lieu on Investigational Immunotherapy Strategies in mCRC
July 2nd 2019Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associate director for clinical research, at the University of Colorado Cancer Center, discusses investigational immunotherapy strategies in metastatic colorectal cancer (mCRC).
Dr. Davis on Caveats of the KEYNOTE-062 Trial Findings in Gastric/GEJ Cancer
June 25th 2019S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses caveats of the phase III KEYNOTE-062 trial findings in gastric and gastroesophageal junction (GEJ) cancer.
Dr. Pollyea Discusses Recent Advances in AML
July 27th 2018Daniel A. Pollyea, MD, MS, assistant professor of Medicine at the University of Colorado Cancer Center and clinical director of Leukemia Services at the CU School of Medicine, discusses recent advances in the treatment landscape of acute myeloid leukemia.
More Than Half of Cervical Cancer Patients Not Receiving Recommended Treatment
November 8th 2016Results of a new study found that less than half of patients with advanced cervical cancer are receiving all 3 of the therapies considered standard of care for the disease: external beam radiation therapy, brachytherapy, and chemotherapy.